Search

In a retrospective study of 9 patients, a 9-year-old boy with grade IV-1 cherubism developed severe hypocalcaemia, paraesthesia, and vomiting after receiving an incorrect route of administration of calcitonin for off-label treatment. The boy's condition worsened after the first injection, which was administered intramuscularly instead of subcutaneously. He was admitted to the hospital and his medication was adjusted, but due to anxiety, the calcitonin treatment was discontinued after one month. [Extracted from the article]

A case report describes a 2-year-old boy who developed hypercalciuria while being treated with topiramate for seizures. The boy also showed lack of efficacy when treated with calcitonin for hypercalciuria. He had other medical conditions, including developmental delays, neuromuscular weakness, and oropharyngeal dysphagia. The boy's hypercalcemia was initially thought to be due to the ketogenic diet and topiramate, but further investigation revealed it was likely a result of the topiramate therapy. Despite treatment with calcitonin, his calcium levels remained elevated, but eventually normalized with adjustments to his diet and hydration. [Extracted from the article]

A 46-year-old man developed COVID-19 pneumonia while being treated with rituximab for autoimmune encephalitis. He had initially been hospitalized and intubated for the encephalitis, but showed improvement after receiving rituximab infusions. However, a month after starting rituximab, he developed a cough and fever and was diagnosed with COVID-19 pneumonia. His condition worsened, leading to respiratory arrest and his eventual death. The severe course of COVID-19 pneumonia was attributed to the rituximab treatment. [Extracted from the article]

A 75-year-old man experienced interstitial pneumonitis while being treated with bicalutamide for prostate adenocarcinoma. He also showed a lack of efficacy when treated with furosemide for acute respiratory distress syndrome. The man had a history of hypertension, hyperlipidemia, and prostate adenocarcinoma, and was receiving bicalutamide and radiation therapies. He was hospitalized due to near syncope and diarrhea, and further complications arose, including ground glass opacities in the chest and bilateral pleural effusions. Despite treatment with antibiotics and steroids, his condition worsened, but eventually improved after discontinuing bicalutamide and receiving high-dose steroid therapy. [Extracted from the article]

An 82-year-old woman developed TAFRO syndrome after receiving the tozinameran COVID-19 vaccine. She also experienced lack of efficacy when treated with furosemide and azosemide for renal and cardiac insufficiency. The woman had a history of drug allergy and reported increased neck thickness after vaccination. She was admitted to the hospital for heart failure and had abnormal blood and urine test results. Treatment with methylprednisolone, prednisolone, and ciclosporin was administered, and her condition improved. She was discharged after 108 days with continued medication. [Extracted from the article]

A 29-year-old pregnant woman experienced lack of efficacy during treatment with calcitonin for hypercalcaemia. She presented with nausea and vomiting and was diagnosed with hyperemesis gravidarum. Further investigation revealed hypercalcaemia, hypophosphataemia, hypokalaemia, and hypomagnesaemia. Despite receiving calcitonin, her calcium levels continued to increase, indicating lack of efficacy. It was later discovered that she had a giant parathyroid adenoma, which was causing the hypercalcaemia. After surgical removal of the adenoma, her calcium levels normalized and she was discharged without complications. The outcome of her pregnancy was not stated. [Extracted from the article]

A 59-year-old woman experienced lack of efficacy during treatment for hypercalcemia with calcitonin, cinacalcet, and pamidronic acid. She was hospitalized due to severe pain and was diagnosed with primary hyperparathyroidism caused by an ectopic parathyroid adenoma complicated with acute pancreatitis. Despite treatment, her calcium levels remained elevated, and she required intermittent hemodialysis and surgical excision of the adenoma. Postoperatively, she was diagnosed with hypocalcemia but improved with treatment and was eventually discharged in stable condition. [Extracted from the article]

A 31-year-old pregnant woman experienced tachyphylaxis, a reduced response to a drug, while being treated with calcitonin for hypercalcaemia. She had a history of nephrolithiasis and presented with pancreatitis and hypercalcaemia during her pregnancy. The woman received various treatments, including continuous fluids and vitamin D supplementation, but developed tachyphylaxis to calcitonin, which led to elevated calcium levels. She underwent surgery for suspected parathyroid adenomas and was discharged with calcium carbonate treatment for primary hyperparathyroidism. [Extracted from the article]

A 31-year-old pregnant woman experienced tachyphylaxis while being treated with calcitonin for hypercalcaemia. She had a history of nephrolithiasis and presented to the emergency department with epigastric pain, nausea, and vomiting, and was diagnosed with pancreatitis. She received fluids and vitamin D for her condition, but her hypercalcaemia persisted. The tachyphylaxis was attributed to the calcitonin treatment, and she underwent surgery for parathyroid adenomas. She was discharged with calcium carbonate medication for primary hyperparathyroidism. [Extracted from the article]

A 22-year-old man developed multisystem inflammatory syndrome after receiving the tozinameran vaccine for COVID-19. He experienced symptoms 9 days after receiving the first dose and had elevated inflammatory markers. He met the criteria for multisystem inflammatory syndrome in adults and was hospitalized for a week with multiple organ dysfunctions. He was treated with immune globulin and steroids, fully recovered, and was discharged after 7 days. The syndrome was considered secondary to the tozinameran vaccine. [Extracted from the article]

A 48-year-old man with a history of severe hidradenitis suppurativa (HS) experienced a lack of efficacy during treatment with calcitonin and pamidronic-acid for hypercalcaemia. He presented with disease deterioration and HS flare, as well as constipation, weakness, anorexia, and weight loss. After investigations, he was diagnosed with metastatic squamous cell carcinoma (SCC). Despite receiving multiple doses of pamidronic-acid and calcitonin, his hypercalcaemia persisted. He was then started on denosumab treatment, which improved his hypercalcaemia. Due to the lack of curative options and poor performance status, he and his family chose to pursue comfort care. [Extracted from the article]

A 71-year-old man with hepatocellular carcinoma (HCC) and alcoholic cirrhosis experienced lack of efficacy during treatment with nivolumab. He was admitted to the ICU with altered mental status and was found to have methicillin-resistant Staphylococcus aureus (MSSA) in cultures. He developed hypercalcemia, which was treated with zoledronic acid and calcitonin. Due to the progression of his HCC and declining quality of life, he chose comfort measures, indicating that nivolumab was not effective for him. [Extracted from the article]

A 59-year-old man developed acute renal failure (ARF) while being treated for brucellosis with rifampicin, gentamicin, and doxycycline. The patient had a history of knee joint pain and knee replacement surgery. He experienced symptoms such as anuria, nausea, and vomiting, and his kidney function tests showed abnormalities. He was admitted to the hospital and underwent hemodialysis. After a change in his anti-brucella treatment and a week of treatment, his renal function gradually improved, and he was discharged. Follow-up tests showed further improvement in his kidney function. [Extracted from the article]

A 67-year-old woman experienced a lack of effectiveness in her treatment for hypercalcemia with calcitonin and cinacalcet. She presented at the hospital with symptoms including intermittent bleeding from the rectum and weakness. Despite treatment with calcitonin and aggressive intravenous fluids, her hypercalcemia did not improve. She then received cinacalcet but ultimately required hemodialysis. Further examination revealed parathyroid adenomas, and surgery to remove them resulted in a gradual return to normal calcium levels, although she remained dependent on dialysis. [Extracted from the article]

A 73-year-old man with end-stage renal disease (ESRD) and hypercalcaemia was treated with calcitonin, cinacalcet, and unspecified bisphosphonates. Despite these treatments, his serum calcium levels remained elevated, indicating a lack of efficacy. Further investigations revealed that he had metastatic prostate cancer, and he was subsequently started on bicalutamide, prednisone, and planned to receive leuprolide as outpatient therapy. This case highlights the challenges in managing hypercalcaemia in patients with ESRD and the need for individualized treatment approaches. [Extracted from the article]

A 63-year-old woman with a history of type 2 diabetes and atrial fibrillation developed hypercalcemia during treatment for an infection in her prosthetic joint. She received calcium sulfate and later sodium chloride and calcitonin, but experienced a lack of efficacy. Her hypercalcemia was resolved after receiving pamidronic acid. [Extracted from the article]

A 45-year-old woman with disseminated ovarian mucinous adenocarcinoma experienced a lack of efficacy with calcitonin and pamidronic acid in treating her hypercalcemia of malignancy. Despite receiving IV pamidronic acid, IM calcitonin, and fluid resuscitation, her serum calcium levels did not normalize. She required dialysis and continuous renal replacement therapy, and her serum calcium began to decrease with further treatment using denosumab, cinacalcet, and etelcalcetide. However, her parathyroid hormone (PTH) levels remained elevated, and she ultimately died from septic shock and multiorgan failure after one week in the hospital. [Extracted from the article]

In a case series of two patients, a 63-year-old man experienced treatment failure with sodium chloride, calcitonin, and ketoconazole while being treated for pneumocystis jirovecii pneumonia (PJP)-associated hypercalcaemia. The man had a history of renal transplantation and was receiving immunosuppressive medicines. He received IV sodium chloride, calcitonin, and ketoconazole for hypercalcaemia but did not respond to treatment. He was subsequently treated with denosumab for hypercalcaemia and clindamycin and primaquine for PJP, which resulted in clinical improvement. [Extracted from the article]

A 68-year-old man experienced a lack of drug effect while being treated for hypercalcemia with calcitonin, cinacalcet, and pamidronic acid. The patient had suffered fractures, a cerebral bleed, and underwent a hemicraniectomy after falling from a ladder. Despite receiving treatment, his calcium levels continued to rise and he remained comatose. However, after undergoing parathyroidectomy to remove an ectopic cystic mass, his calcium and parathyroid hormone levels improved and he eventually regained consciousness. [Extracted from the article]

A 42-year-old man with a history of polysubstance abuse experienced lack of efficacy during treatment with calcitonin for hypercalcaemia. He presented with septic shock and cocaine intoxication, leading to cardiac arrest, severe muscle damage, and acute kidney injury. Despite receiving treatment with calcitonin, his calcium levels continued to rise, indicating a lack of efficacy. Unfortunately, his clinical condition deteriorated and he ultimately passed away. [Extracted from the article]

A 57-year-old woman developed pulmonary edema while being treated with trabectedin for leiomyosarcoma. She had a history of interstitial lung disease, adriamycin-induced pneumonitis, chronic obstructive pulmonary disease (COPD), and former smoking. After receiving the first dose of trabectedin, she experienced worsening shortness of breath and chest imaging revealed new lung abnormalities. She was treated with diuresis and antibiotics, and her condition improved. However, after the second dose of trabectedin, she experienced worsening symptoms again, but her condition improved with high-dose steroids and diuretics. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 17-year-old girl exhibited rebound hypercalcaemia following withdrawal of calcitonin. She exhibited lack of efficacy during treatment with sodium chloride for hypercalcaemia. She exhibited treatment non-compliance with cinacalcet for hypercalcaemia. She received sodium chloride, calcitonin and cinacalcet for hypercalcaemia during pregnancy [not all dosages and routes stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventAn 81-year-old man exhibited lack of efficacy during treatment with calcitonin and unspecified loop diuretic for hypercalacemia [routes and dosages not stated]. [Extracted from the article]

A case report published in Reactions Weekly describes a child who experienced a hypercalcaemic crisis while being treated with calcitonin for hypercalcemia. The patient initially showed a temporary decrease in serum calcium levels after receiving calcitonin, but quickly returned to a hypercalcaemic crisis. This reaction was believed to be caused by downregulated calcitonin receptors in the bone and kidneys as a result of calcitonin therapy. The report does not provide information on the patient's age, sex, dosage of calcitonin, duration of treatment, or outcome. [Extracted from the article]

The woman, who had a history of GCLJ, received treatment with calcitonin and peginterferon [PEG-interferon; I routes and dosages not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective cohort study conducted between January 2012 and December 2021, involving 20 patients, et al. 24-year-old woman was described, who exhibited no response to calcitonin and peginterferon for giant cell lesion of the jaw (GCLJ). Thereafter, the woman received treatment with denosumab. [Extracted from the article]

Milk-Alkali Syndrome: How Electronic Medical Record Open Notes Helped to Rule Out Cancer. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose A 64-year-old man developed milk-alkali syndrome following intentional drug misuse with calcium-carbonate for gastroesophageal reflux disease (GERD) at an overdose. The diagnosis of milk-alkali syndrome secondary to intentional drug misuse with calcium-carbonate at an overdose was made, which explained the hypercalcaemia and associated symptoms. [Extracted from the article]

Notably, she had a remarkable medical history for diabetes mellitus (DM), congestive heart failure and chronic kidney disease stage II secondary to DM. Hence, a lack of efficacy was reported for calcitonin, denosumab and sodium-chloride. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 79-year-old woman exhibited lack of efficacy during treatment with unspecified bisphosphonates, calcitonin, denosumab and sodium-chloride for hypercalcaemia [ I routes and dosages not stated i ]. [Extracted from the article]

However, the hypercalcaemia of malignancy was refractory to denosumab, calcitonin and zoledronic-acid which indicated a lack of efficacy. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 75-year-old man exhibited a lack of efficacy during treatment with calcitonin, denosumab and zoledronic-acid for hypercalcaemia [ I routes and dosages not stated i ]. The man, who had prostate cancer and sarcomatoid mesothelioma presented to the emergency department [ED] due to hypercalcaemia. [Extracted from the article]